title: Recombinational construction in Escherichia coli of infectious adenoviral genomes.
abstract: A two-step gene replacement procedure was developed that generates infectious adenoviral genomes through homologous recombination in Escherichia coli. As a prerequisite, a human adenovirus serotype 5 (Ad5)-derived genome was first introduced as a PacI restriction fragment into an incP-derived replicon which, in contrast to ColE1-derivatives (e.g., pBR322 or pUC plasmids), is functional in a polA mutant of E. coli. Any modification can be introduced at will following two consecutive homologous recombinations between the incP/Ad5 replicon and the ColE1 plasmid. The overall procedure requires only the in vitro engineering of the ColE1-derivative by flanking the desired modification with small stretches of identical sequences. In the first step, a cointegrate between the tetracycline-resistant incP/Ad5 replicon and the kanamycin-resistant ColE1-derivative is selected by growing the polA host in the presence of both antibiotics. Resolution of this cointegrate is further selected in sucrose growth conditions due to the loss of a conditional suicide marker (the sacB gene of Bacillus subtilis) present in the ColE1 plasmid, leading to unmodified and modified incP/Ad5 replicons that can be differentiated upon restriction analysis. Consecutive rounds of this two-step cloning procedure allowed the introduction of multiple independent modifications within the virus genome, with no requirement for an intermediate virus. The potential of this procedure is demonstrated by the recovery of several E1E3E4-deleted adenoviruses following transfection of the corresponding E. coli-derived genomes in IGRP2 cells.
authors.affiliation: Rhône-Poulenc Rorer Gencell, Centre de Recherche de Vitry-Alfortville,Vitry-Sur-Seine, France, joel.crouzet@rp.fr
authors.forename: J
authors.initials: J
authors.lastname: Crouzet
authors.forename: L
authors.initials: L
authors.lastname: Naudin
authors.forename: C
authors.initials: C
authors.lastname: Orsini
authors.forename: E
authors.initials: E
authors.lastname: Vigne
authors.forename: L
authors.initials: L
authors.lastname: Ferrero
authors.forename: A
authors.initials: A
authors.lastname: Le Roux
authors.forename: P
authors.initials: P
authors.lastname: Benoit
authors.forename: M
authors.initials: M
authors.lastname: Latta
authors.forename: C
authors.initials: C
authors.lastname: Torrent
authors.forename: D
authors.initials: D
authors.lastname: Branellec
authors.forename: P
authors.initials: P
authors.lastname: Denèfle
authors.forename: J F
authors.initials: JF
authors.lastname: Mayaux
authors.forename: M
authors.initials: M
authors.lastname: Perricaudet
authors.forename: P
authors.initials: P
authors.lastname: Yeh
mesh_terms: D017498:Adenovirus E1 Proteins / Q000235:genetics; D017503:Adenovirus E3 Proteins / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics* / Q000254:growth & development / Q000472:pathogenicity; D003001:Cloning, Molecular / Q000379:methods*; D004926:Escherichia coli / Q000235:genetics; D005818:Genetic Engineering / Q000379:methods*; D005819:Genetic Markers; D016679:Genome, Viral; D007613:Kanamycin Resistance; D010957:Plasmids / Q000235:genetics; D011995:Recombination, Genetic; D012093:Replicon; D013753:Tetracycline Resistance
chemical_list: D017498:Adenovirus E1 Proteins; D017503:Adenovirus E3 Proteins; D005819:Genetic Markers